Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 4.60% is 15% above its 5-year average of 4.01%, near the high end of its 5-year range (1.14%–5.10%).
4.56% below its 12-month average of 4.82%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 0.86%.
RETURN ON ASSETS (ROA)
4.60%
RETURN ON ASSETS (ROA) AVG TTM
4.82%
RETURN ON ASSETS (ROA) AVG 3Y
4.76%
RETURN ON ASSETS (ROA) AVG 5Y
4.01%
RETURN ON ASSETS (ROA) AVG 10Y
3.84%
RETURN ON ASSETS (ROA) AVG 15Y
4.87%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-4.56%
CURRENT VS 3Y AVG
-3.36%
CURRENT VS 5Y AVG
+14.57%
CURRENT VS 10Y AVG
+19.85%
CURRENT VS 15Y AVG
-5.52%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
-10.51%
vs the sector median at left
IQVIA Holdings Inc.
Market Cap
$44.39B
Return on Assets (ROA)
4.60%
TTM Avg
4.82%
3Y Avg
4.76%
5Y Avg
4.01%
Market Cap
$45.71B
Return on Assets (ROA)
1.77%
TTM Avg
-0.35%
3Y Avg
-1.89%
5Y Avg
-2.43%
Market Cap
$42.42B
Return on Assets (ROA)
10.31%
TTM Avg
10.56%
3Y Avg
11.14%
5Y Avg
10.55%
Market Cap
$40.29B
Return on Assets (ROA)
33.11%
TTM Avg
29.29%
3Y Avg
27.30%
5Y Avg
27.52%
Market Cap
$49.37B
Return on Assets (ROA)
7.25%
TTM Avg
19.91%
3Y Avg
18.29%
5Y Avg
17.04%
Market Cap
$51.23B
Return on Assets (ROA)
1.85%
TTM Avg
3.00%
3Y Avg
3.04%
5Y Avg
2.95%
Market Cap
$54.49B
Return on Assets (ROA)
2.99%
TTM Avg
2.96%
3Y Avg
2.15%
5Y Avg
1.30%
Market Cap
$33.41B
Return on Assets (ROA)
-6.14%
TTM Avg
-2.29%
3Y Avg
0.04%
5Y Avg
0.75%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | $44.39B | 4.60% | 4.82% | 4.76% | 4.01% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $45.71B | 1.77% | -0.35% | -1.89% | -2.43% |
| Agilent Technologies, Inc. (A)vs › | $42.42B | 10.31% | 10.56% | 11.14% | 10.55% |
| Humana Inc. (HUM)vs › | $47.61B | 2.23% | 2.52% | 4.20% | 5.49% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $40.29B | 33.11% | 29.29% | 27.30% | 27.52% |
| Edwards Lifesciences Corporation (EW)vs › | $49.37B | 7.25% | 19.91% | 18.29% | 17.04% |
| Becton, Dickinson and Company (BDX)vs › | $51.23B | 1.85% | 3.00% | 3.04% | 2.95% |
| Cardinal Health, Inc. (CAH)vs › | $54.49B | 2.99% | 2.96% | 2.15% | 1.30% |
| Centene Corp. (CNC)vs › | $33.41B | -6.14% | -2.29% | 0.04% | 0.75% |
| ResMed Inc. (RMD)vs › | $33.28B | 16.99% | 17.06% | 15.57% | 14.60% |
ROA
4.6%
ROE
22.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 4.54% |
| 2024-12-31 | 5.10% |
| 2023-12-31 | 5.09% |
| 2022-12-31 | 4.31% |
| 2021-12-31 | 3.91% |
| 2020-12-31 | 1.14% |
| 2019-12-31 | 0.82% |
| 2018-12-31 | 1.15% |
| 2017-12-31 | 5.76% |
| 2016-12-31 | 0.54% |
| 2015-12-31 | 9.86% |
| 2014-12-31 | 10.78% |
| 2013-12-31 | 7.39% |
| 2012-12-31 | 7.10% |
| 2011-12-31 | 10.41% |
| 2010-12-31 | 0.00% |
